{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-007396","form_type":"8-K","ticker":"SNGX","cik":"0000812796","company_name":"SOLIGENIX, INC.","filed_at":"2023-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.334750+00:00","generated_at":"2026-06-16T05:46:09.208365+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Soligenix obtains exclusive option for Phase 2/3-ready topical Pentoxifylline in Behçet's Disease","bullets":["Exclusive option agreement with Silk Road Therapeutics to acquire topical Pentoxifylline for mucocutaneous ulcers in Behçet's Disease.","BD affects ~18,000 US, 80,000 EU patients; orphan disease with no cure, current treatments limited.","Phase 2 trial showed 83% of PTX patients had ulcer shrinkage by Day 2 vs 19% colchicine (p<0.0001).","By Day 4, 72% on PTX had undetectable ulcer vs 29% colchicine; no serious adverse events.","Program is Phase 2/3-ready; Soligenix plans FDA discussions on trial design."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-007396","json":"https://secwatch.observer/filing/0001558370-23-007396.json","markdown":"https://secwatch.observer/filing/0001558370-23-007396.md","text":"https://secwatch.observer/filing/0001558370-23-007396.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/812796/000155837023007396/0001558370-23-007396-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/812796/000155837023007396/sngx-20230501x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T05:46:09.208365+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}